RxDoctor Payments Data

Thomas Walters, MD

Ophthalmology · Austin, TXNPI 1609852664

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,250 of the $15,837 with a category attached, or 64.7%. AbbVie accounts for 69.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $11,119 and has fallen 93.2% since, to $760 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,837in general payments, 2019–2025

Across 116 payments — averaging $136.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$11K
  • Alcon$3K
  • Carl Zeiss Meditec USA, Inc.$510
  • Rxsight Inc$497
  • Carl Zeiss Meditec, Inc.$387
  • Sun Pharmaceutical Industries Inc.$232
  • plus $618 from 8 others
$2,391,903in research payments, 2019–2025

Across 481 payments — averaging $4972.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1.6M
  • Alcon Research LLC$345K
  • Ocular Therapeutix, Inc.$291K
  • Shire North American Group Inc$44K
  • Sun Pharmaceutical Industries Inc.$43K
  • Aerie Pharmaceuticals, Inc.$30K
  • plus $34K from 3 others

What the payments were for

  • Consulting fees$10,25065%
  • Food & beverage$5,52335%
  • Other$640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,837 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$388,380
Medicare patients
515
Services billed
1,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Latanoprost79$953
Prednisolone Acetate19$904
MoxifloxacinMoxifloxacin Hcl15$366
Timolol Maleate22$195

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →